Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01086384 · ClinicalTrials.gov registry record · Phase 3
Asthma Exacerbation Study
A Phase 3 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,020
- Enrollment target
- 20
- Study locations
NCT01086384 is a Phase 3 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,020 participants, above the 1,558-participant average among 374 other Asthma trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT01086384, a Phase 3 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
Conditions Studied
Interventions
- DRUG Fluticasone Furoate/GW642444
- DRUG Fluticasone furoate
Study Locations (20)
California
- GSK Investigational Site - Bell Gardens
- GSK Investigational Site - Fresno
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Mission Viejo
- GSK Investigational Site - Napa
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - Riverside
- GSK Investigational Site - Rolling Hills Estates
- GSK Investigational Site - Roseville
- GSK Investigational Site - San Diego
- GSK Investigational Site - Stockton
- GSK Investigational Site - Torrance
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Mobile
- GSK Investigational Site - Oxford
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Scottsdale
- GSK Investigational Site - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,020 participants |
| Start Date | 2010-02-22 |
| Est. Completion | 2011-09-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01086384
The ClinicalTrials.gov registry entry for NCT01086384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,558-participant average among 374 other Asthma trials with a reported enrollment target (30% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Fluticasone Furoate/GW642444 is the first listed.
NCT01086384 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT01086384 about?
NCT01086384 is a clinical study titled "Asthma Exacerbation Study". This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
What is the current status of trial NCT01086384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,020 participants. The study started on 2010-02-22. Estimated completion is 2011-09-15.
What conditions does trial NCT01086384 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01086384?
The interventions under investigation include: Fluticasone Furoate/GW642444 (DRUG), Fluticasone furoate (DRUG).
Who is sponsoring clinical trial NCT01086384?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01086384 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.